{"filings":[{"id":2108236,"accession_number":"0001193125-26-338438","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-08-06T21:15:48+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solid Biosciences upsizes ATM equity facility to $200M; $85M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for up to $200M in common stock sales under existing ATM agreement with Jefferies.","Prior supplement for $85M exhausted; $85M in gross proceeds already raised.","New supplement replaces prior; no further sales under old supplement.","Legal opinion from WilmerHale attached as Exhibit 5.1.","Shares registered under existing shelf registration statement (S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972640,"accession_number":"0001193125-26-265804","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-06-10T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"Solid Biosciences shareholders approve doubling of authorized common stock to 480M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved charter amendment increasing authorized common shares from 240M to 480M; filed June 10, 2026.","Elected Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan with overwhelming votes (73M+ each).","Ratified PricewaterhouseCoopers as independent auditor for FY2026 with 86.4M votes for, 70K against.","Advisory say-on-pay passed with 72.6M votes for and 6.2M against; broker non-votes 7.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94859,"accession_number":"0001193125-26-151259","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Solid Biosciences reclassifies director Ilan Ganot from Class III to Class I to balance board composition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ilan Ganot resigned from Class III effective 4:00 p.m. ET on April 10, 2026.","Board reduced Class III to three directors and increased Class I to three, appointing Ganot to Class I with term expiring at 2028 Annual Meeting.","Ganot's compensation arrangements unchanged; no compensation due for resignation or appointment.","Company will seek advisory ratification of Ganot's appointment as Class I Director at 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107541,"accession_number":"0001193125-26-102489","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.","Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.","Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.","Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.","FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107540,"accession_number":"0001193125-26-096709","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.","Preliminary cash, equivalents and securities ~$187.9M as of Dec 31, 2025 (unaudited).","Net proceeds extend runway into H1 2028; funds pipeline development, BD, and G&A.","Investors include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, and others.","Private placement expected to close March 9, 2026; Leerink and Citi lead placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123889,"accession_number":"0001193125-25-262795","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.","Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.","Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.","Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.","Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158257,"accession_number":"0000950170-25-086215","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"SLDB stockholders approve doubling authorized shares to 240M and adding 9M shares to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 120M to 240M via Certificate of Amendment filed June 12, 2025.","Equity plan amended to add 9M shares and modify evergreen provision to 6% annual increase from 2026.","Class I directors Alexander Cumbo and Sukumar Nagendran re-elected with 95% and 92% of votes cast, respectively.","PricewaterhouseCoopers ratified as auditor for FY2025 with 68.9M votes for, 18.8K against.","Say-on-pay advisory vote approved with 57.1M for vs. 5.1M against; 6.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158256,"accession_number":"0000950170-25-072792","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solid Biosciences ups ATM offering capacity to $85M; $10.5M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 15, 2025 to increase ATM offering from $75M to $85M.","Prior prospectus had $75M capacity; $10.5M in gross proceeds sold as of filing date.","Offering conducted under existing S-3 shelf registration statement via Jefferies LLC.","Legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176637,"accession_number":"0001193125-25-028691","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences prices $200M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.","Net proceeds estimated at $187.5M after underwriting discounts and expenses; offering expected to close Feb 19, 2025.","Investors include Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, others.","Jefferies, Leerink Partners, William Blair act as joint book-runners; H.C. Wainwright as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176636,"accession_number":"0001193125-25-028146","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.","Company estimates cash runway into first half of 2027, but notes offering alone may not fully fund development of all candidates.","Remaining proceeds for general corporate purposes; existing cash and securities combined for operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176635,"accession_number":"0001193125-25-028123","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.","Mean reductions in muscle injury biomarkers: CK -57%, AST -45%, ALT -54%, LDH -60% at Day 90.","Two participants at Day 180 showed mean LVEF increase of 8% from baseline; no serious adverse events or TMA observed.","Preliminary cash, cash equivalents and available-for-sale securities of ~$148.9M as of Dec 31, 2024.","Company plans mid-2025 FDA meeting to discuss accelerated approval for SGT-003; enrollment ongoing with 7th dosed Feb 17."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227974,"accession_number":"0001193125-24-159143","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Solid Biosciences directors Koppel and Shah resign; shareholders approve doubling authorized shares to 120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adam Koppel and Rajeev Shah resigned from the Board effective June 11, 2024; no disagreement cited.","Shareholders approved increase of authorized common stock from 60M to 120M shares.","Equity incentive plan amended to add 2M shares; total available for issuance increased accordingly.","Four Class III directors elected: Martin Freed, Ilan Ganot, Georgia Keresty, Ian Smith.","Advisory vote on executive compensation held every year; PricewaterhouseCoopers ratified as auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246728,"accession_number":"0001193125-24-003882","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences raises $108.9M in private placement; preliminary cash $123.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$108.9M from 16,973,103 shares at $5.53/share and 2,712,478 pre-funded warrants at $5.529 each.","Net proceeds ~$104.1M after fees; closing expected January 11, 2024.","Preliminary unaudited cash, equivalents and securities of $123.9M as of Dec 31, 2023 (excluding PIPE proceeds).","Clinical milestones: SGT-003 safety update mid-2024, initial data Q3 2024; SGT-501 IND submission Q1 2025.","Investors include Perceptive Advisors, Adage Capital, Deerfield, Invus, Janus Henderson, Vestal Point, Bain Capital, RA Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264174,"accession_number":"0001193125-23-277552","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences gets FDA IND clearance for Duchenne gene therapy SGT-003; Phase 1/2 trial planned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clears IND for SGT-003, a next-generation microdystrophin gene therapy for Duchenne muscular dystrophy.","Phase 1/2 trial (SGT-003-101) will be first-in-human, open-label, multicenter; dose 1E14vg/kg as single IV infusion.","Cohort 1 enrolls patients aged 4 to <6 years; minimum 3 patients per cohort with potential expansion; 5-year follow-up.","SGT-003 uses capsid AAV-SLB101 with R16/R17 nNOS-binding domains; preclinical data showed improved biodistribution vs AAV9.","Company expects to submit for IRB approval and commence patient screening shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300244,"accession_number":"0001193125-23-164486","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Solid Biosciences stockholders elect four Class II directors, ratify auditor, approve ESPP amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Clare Kahn, Adam Koppel, Adam Stone, Lynne Sullivan as Class II directors to 2026; votes ranged 13.6M–14.2M for, 76K–664K withheld.","Ratified PricewaterhouseCoopers LLP as auditor for FY 2023 with 15.3M for, 4.9K against, 5.5K abstain.","Approved amendment to 2021 ESPP increasing shares available for issuance; 13.6M for, 679K against, 4K abstain.","All results from June 6, 2023 Annual Meeting; broker non-votes of ~1.1M on director election and ESPP amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300243,"accession_number":"0001193125-23-150518","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Carl Morris resigns as CSO Neuromuscular; Jennifer Marlowe to become CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl Morris resigns as Chief Scientific Officer, Neuromuscular, effective July 14, 2023.","Jennifer Marlowe, current CSO Friedreich's Ataxia and Cardiac Pipeline, will assume role of CSO.","Morris receives severance: 1 year base salary, COBRA for 12 months, $172,200 lump sum (100% of 2023 target bonus).","Morris to enter consulting agreement through March 31, 2024; time-based equity awards continue vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320283,"accession_number":"0001193125-23-074426","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Solid Biosciences presents one-year IGNITE DMD data; SGT-001 program concluded","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-year data: mean 69.8% normal dystrophin by Western blot in 2E14 vg/kg cohort (Pt.5 at 18 months).","Motor function: 6MWT and NSAA showed positive mean change from baseline at 1 year.","Pulmonary function: FVC % predicted and FEV1 % predicted improved from baseline.","Safety: 2/9 SAEs related to SGT-001 (thrombocytopenia, hepatotoxicity, systemic inflammatory response).","SGT-001 program concluded; next-gen SGT-003 with novel capsid in IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320282,"accession_number":"0001193125-23-068478","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Solid Biosciences holds less than $1M at Silicon Valley Bank; no material exposure","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Cash balance at SVB is de minimis (<$1.0M) per March 13, 2023 filing.","Remaining capital resources held at other institutions and money market funds.","Disclosure follows SVB collapse; company confirms minimal direct impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320281,"accession_number":"0001193125-23-004189","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.","Preliminary cash and investments $214M as of Dec 31, 2022 (unaudited).","Company anticipates submitting IND for SGT-003 in H2 2023 with patient dosing in late 2023.","Tan previously served as CFO of Selecta Biosciences and Treasurer at Sarepta Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338422,"accession_number":"0001193125-22-298016","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["1.01","2.01","2.05","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Solid Biosciences closes AavantiBio acquisition, $75M PIPE, Bo Cumbo named CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 1,354,258 shares of common stock plus $1,000 cash to AavantiBio equityholders upon close.","Closed $75.0M private placement with investors including Perceptive, RA Capital, Bain Capital Life Sciences.","Appointed Alexander (Bo) Cumbo as President and CEO, effective Dec 2, 2022; former AavantiBio CEO.","Board approved 18% workforce reduction; expects ~$3.2M severance charge in Q4 2022.","Combined company holds ~$215M cash and investments; expected to fund operations into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338421,"accession_number":"0001193125-22-296577","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Solid Biosciences stockholders approve share issuance for AavantiBio merger and amended equity plan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved issuance of shares for the acquisition of AavantiBio under the Merger Agreement (4,054,470 for, 41,480 against).","Approved amended 2020 Equity Incentive Plan, increasing share reserve by 866,666 to 1,533,333 shares plus annual evergreen 5% of outstanding shares.","Equity plan proposal passed with 3,480,064 for and 614,534 against.","Annual increase feature begins fiscal year 2023 up to fiscal 2032 at Board discretion.","Approval removes key condition for closing the AavantiBio acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338420,"accession_number":"0001193125-22-271105","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Solid Biosciences effects 1-for-15 reverse stock split, reduces authorized shares to 60M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse stock split effective Oct. 27, 2022; trading on split-adjusted basis begins Oct. 28.","Authorized common shares reduced from 300M to 60M (20M post-split then tripled per certificate amendment).","Stockholders approved the amendment at the June 7, 2022 annual meeting; no fractional shares, cash in lieu.","Outstanding options, warrants, and RSUs adjusted proportionally per their terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355786,"accession_number":"0001193125-22-255495","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Solid Biosciences to acquire AavantiBio; announces $75M private placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: Solid acquires AavantiBio through transitory subsidiary merger; AavantiBio survives as wholly owned.","Private placement of 159,574,463 shares at $0.47/share for ~$75M from accredited investors.","Closing requires stockholder approval; private placement closes immediately after merger.","Combined pipeline includes SGT-003 for Duchenne, AVB-202 for Friedreich's ataxia, AVB-401 for BAG3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355785,"accession_number":"0001193125-22-254807","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences acquires AavantiBio in stock deal, raises $75M PIPE, appoints new CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires AavantiBio for 15% of SLDB common stock plus $1,000; AavantiBio lead program in Friedreich's Ataxia gene therapy.","Concurrent $75M PIPE at $0.47/share; PIPE shares equal ~159.6M shares, closing after merger.","Current CEO Ilan Ganot resigns effective closing; Alexander (Bo) Cumbo (AavantiBio CEO) to become new CEO; Adam Koppel joins board.","Support agreements: 79% of AavantiBio and 29.8% of SLDB stockholders commit to vote in favor.","Closing conditions include Nasdaq listing approval and stockholder approvals; termination fee $310k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355784,"accession_number":"0001193125-22-218018","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).","Cash and investments $162.9M as of June 30, 2022; estimated runway into Q2 2024.","Transition to transient transfection manufacturing for SGT-001; expects to continue dosing patients in 2023.","Next-gen candidate SGT-003 on track for mid-2023 IND submission; capsid shows improved muscle tropism vs AAV9.","Long-term data from IGNITE DMD trial of SGT-001 expected in early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374065,"accession_number":"0001193125-22-171086","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Solid Biosciences stockholders approve reverse stock split and authorized share increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors Huffines, Nagendran, Shah with ~65.9M votes each.","Ratified PricewaterhouseCoopers as auditor for FY2022: 87.3M for, 226.9K against.","Approved reverse stock split at ratio of 1:5 to 1:15, board to set exact ratio before 2023 annual meeting.","Approved increase in authorized shares to 300M multiplied by 3x the reverse split ratio.","Reverse split and share increase subject to board discretion; may be abandoned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374064,"accession_number":"0001193125-22-168329","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Solid Biosciences receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency letter on May 31, 2022 for failing to meet $1.00 minimum bid price requirement over 30 consecutive business days.","Company has 180 calendar days, until November 28, 2022, to regain compliance by closing at $1.00 or more for 10 consecutive days.","If not compliant by November 28, may transfer to Nasdaq Capital Market or consider a reverse stock split to cure deficiency.","There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374063,"accession_number":"0001193125-22-121607","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Solid Biosciences restructures, cuts 35% of staff; Q1 net loss $25.3M; COO resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduced ~35% to align resources behind SGT-001 and SGT-003; cash runway extended into Q2 2024.","COO Joel Schneider to resign effective May 27, 2022 to become CEO of a private gene therapy company.","Q1 net loss $25.3M vs $16.9M YoY; collaboration revenue $1.9M (down from $3.3M); R&D expense $19.9M.","Cash, equivalents and securities $180.1M as of March 31, 2022.","SGT-003 IND submission expected early 2023; SGT-001 transitioning to commercial-scale manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374062,"accession_number":"0001193125-22-095085","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["5.05"],"status":"ready","headline":"Solid Biosciences board adopts new Code of Business Conduct and Ethics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved new Code of Business Conduct and Ethics on March 30, 2022.","New code replaces prior code in its entirety; no explicit or implicit waivers granted.","Code applies to all employees, officers, directors of Solid Biosciences and its subsidiaries.","Full text posted at https://investors.solidbio.com/governance/governance-documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392689,"accession_number":"0001193125-22-005120","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.","Ninth patient dosed in IGNITE DMD Phase I/II trial for SGT-001 in Nov 2021 using second-gen manufacturing.","Plans to share additional SGT-001 expression, functional, pulmonary data in H1 2022.","SGT-003 IND-enabling studies in 2022; IND filing targeted early 2023.","Board Chair Ian F. Smith appointed Executive Chair effective Jan 10, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429812,"accession_number":"0001193125-21-286070","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2021-09-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.","FEV1 % predicted improved in all 5 evaluable dosed patients (+2.8% to +15.5%); all 3 evaluable controls declined (-8.7% to -17.0%).","Data from first 6 patients in Phase I/II IGNITE DMD trial of SGT-001; presented at Child Neurology Society 50th Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429809,"accession_number":"0001193125-21-282945","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K/A","filed_at":"2021-09-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Solid Biosciences corrects FVC data error for patient five in IGNITE DMD trial; mean improvement +8.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected 1.5-year FVC change for patient five: +22.5% (previously reported incorrectly).","Mean percent predicted FVC improvement for patients 4-6: +8.5% (range +0.6% to +22.5%).","Mean difference vs natural history decline of 7.5% was +16.0% over 1.5 years.","All three patients treated with 2E14 vg/kg SGT-001 show stability or improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429811,"accession_number":"0001193125-21-279962","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.","6MWT mean increase 15.3 meters vs expected 63.5-meter decline; difference +78.8 meters.","Percent predicted FVC improved 4.1% vs expected 7.5% decline; difference +11.6%.","PODCI global, sports, transfer, upper-body scales showed sustained improvements at 1.5 years.","No new drug-related safety findings in patients with post-dosing periods up to 3.5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429810,"accession_number":"0001193125-21-247694","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.","R&D expenses $15.5M (up from $13.4M) driven by SGT-001 manufacturing and clinical costs.","Cash, cash equivalents and securities $249M as of June 30, 2021; runway into Q4 2022.","IGNITE DMD trial: next patient dosing anticipated Q4 2021; no new safety findings in patients 1-8 over 90 days to >3 years.","Targeting IND submission for next-generation SGT-003 in early-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}